Chinese biotech Everest signs $550M+ licensing deal for BTK inhibitors on heels of Covid-19 pact
Everest Medicines is on a roll with two licensing deals in one week.
The Shanghai-based biotech has paid Sinovent and SinoMab $12 million upfront for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
